NetworkNewsBreaks – VistaGen Therapeutics Inc. (
Post# of 130
(Total Views: 241)
Posted On: 04/27/2021 3:28:51 PM
NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s appointment. “Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas,” said Shawn Singh, chief executive officer of VistaGen. “Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive experience and understanding of the entire life cycle of drug development. As we expand our business and pursue our mission to improve mental health and well-being for individuals in the U.S. and abroad, her tremendous leadership, creativity and expertise will be invaluable to VistaGen.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s appointment. “Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas,” said Shawn Singh, chief executive officer of VistaGen. “Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive experience and understanding of the entire life cycle of drug development. As we expand our business and pursue our mission to improve mental health and well-being for individuals in the U.S. and abroad, her tremendous leadership, creativity and expertise will be invaluable to VistaGen.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VistaGen Therapeutics, Inc. (VTGN) Stock Research Links
Scroll down for more posts ▼